This systematic review to support the 2016 update of the US Preventive Services Task Force Recommendation Statement on lipid screening in childhood and adolescence for detection of multifactorial dyslipidemia summarizes published evidence about the benefits and harms of screening.
This Recommendation Statement from the US Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger.
This Viewpoint discusses the need to achieve consensus around management strategies for patients with hyperlipidemia when proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors enter the marketplace.
This study uses Framingham cohort data to assess whether the 2013 American College of Cardiology/American Heart Association guidelines for cholesterol management improve identification of adults at higher risk of cardiovascular events compared with the 2004 Adult Treatment Panel III guidelines.
Ikeda and coauthors determine whether daily, low-dose aspirin reduces the incidence of cardiovascular (CV) events compared with no aspirin in older Japanese patients with multiple atherosclerotic risk factors.
This Editorial discusses when aspirin should be used to prevent vascular events and the factors that should be discussed in decision making.
This Viewpoint discusses the use of screening coronary computed tomographic angiography in asymptomatic patients with diabetes.
This JAMA Clinical Evidence Synopsis discusses the association of fixed-dose combination therapy (polypill) and a reduced risk for cardiovascular disease (CVD).
This Clinical Review reports that treatment of hypercholesterolemia for patients at risk for atherosclerotic cardiovascular disease should start before age 80 years.